-
1.发明公开公开(公告)号：US20240245811A1
公开(公告)日：2024-07-25
申请号：US18040021
申请日：2021-07-30
Applicant: Paul Scherrer Institut
Inventor： Michal Grzmil , Roger Schibli , Martin Behe , Alain Blanc , Yun Qin
CPC classification number: A61K51/088 , A61P35/00 , C07K7/08
Abstract: An alpha radiolabeled gastrin analogue is used in peptide receptor radionuclide therapy (PRRT) applications. In particular, an alpha radiolabeled gastrin analogue, which exhibits excellent biodistribution and therapeutic efficacy while toxicity for healthy tissues is prevented and/or reduced. The alpha radiolabeled gastrin analogue is used in methods of treating cholecystokinin (CCKB) receptor positive diseases.
-
公开(公告)号：US11649268B2
公开(公告)日：2023-05-16
申请号：US16309805
申请日：2017-06-14
Applicant: ETH ZURICH , PAUL SCHERRER INSTITUT
Inventor： Mamta Chabria , Alessandra Moscaroli , Simon Arnoldini , Samuel Hertig , Viola Vogel , Martin Behe , Roger Schibli
CPC classification number: C07K14/435 , A61K47/549 , A61K47/64 , A61K49/0056 , A61K49/14 , A61K49/221 , A61K51/0497 , A61K38/00
Abstract: The present invention is directed to a composition comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic agent, a nucleic acid encoding a fusion polypeptide comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic polypeptide agent as well as a corresponding recombinant vector and host cell comprising such a nucleic acid and preferably expressing said fusion polypeptide. The invention also relates to a kit of parts comprising at least one fibronectin binding polypeptide (FnBP), at least one diagnostic or therapeutic agent, and optionally one or more chemical agents for linking the fibronectin binding polypeptide (FnBP) to the diagnostic or therapeutic agent. In addition, the present invention intends said composition, nucleic acid, vector, host cell and kit for use in the therapeutic or prophylactic treatment of a disease, preferably a disease associated with abnormal fibronectin accumulation such as cancer, fibrosis or immune diseases.
-
公开(公告)号：US09427478B2
公开(公告)日：2016-08-30
申请号：US14582040
申请日：2014-12-23
Applicant: Innate Pharma , Paul Scherrer Institut
Inventor： Delphine Bregeon , Patrick Dennler , Christian Belmant , Laurent Gauthier , François Romagne , Eliane Fischer , Roger Schibli
IPC: A61K47/48 , C07K16/00 , C07K16/30 , C07K19/00 , A61K31/5517
CPC classification number: A61K47/48569 , A61K31/5517 , A61K47/48384 , A61K47/48715 , A61K47/6801 , A61K47/6803 , A61K47/6851 , A61K47/6889 , C07K16/30 , C07K2317/24 , C07K2317/40
Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.
Abstract translation: 本申请涉及免疫球蛋白的酶官能化方法，特别是与药物的方法。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法。
-
公开(公告)号：US20150165064A1
公开(公告)日：2015-06-18
申请号：US14582040
申请日：2014-12-23
Applicant: Innate Pharma , Paul Scherrer Institut
Inventor： Delphine Bregeon , Patrick Dennler , Christian Belmant , Laurent Gauthier , François Romagne , Eliane Fischer , Roger Schibli
IPC: A61K47/48 , A61K31/5517
CPC classification number: A61K47/48569 , A61K31/5517 , A61K47/48384 , A61K47/48715 , A61K47/6801 , A61K47/6803 , A61K47/6851 , A61K47/6889 , C07K16/30 , C07K2317/24 , C07K2317/40
Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.
Abstract translation: 本申请涉及免疫球蛋白的酶官能化方法，特别是与药物的方法。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法。
-
公开(公告)号：US11623014B2
公开(公告)日：2023-04-11
申请号：US17127265
申请日：2020-12-18
Applicant: Paul Scherrer Institut
Inventor： Martin Behe , Roger Schibli
IPC: A61K51/08 , A61K38/22 , C07K14/575 , C07K14/595 , C07B59/00 , C07K1/13 , C07K7/08 , G01N33/574
Abstract: A gastrin analogue shows high uptake in CCK-2 receptor positive tumors and simultaneously a very low accumulation in the kidneys. This is achieved by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is an amino acid replacing methionine and X is a chemical group attached to the peptide for diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. Very suitable compounds with respect to a high tumor to kidney ratio are mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine which can be oxidized easily which is a disadvantage for clinical application under GMP due to the forms which may occur. The elimination of the methionine leads to a lower affinity to oxidation which in general favors the tumor-kidney-ratio. Ideally, the methionine is replaced by norleucine. This PP-F11N mini gastrin exhibits currently the best tumor-kidney-ratio and is the most promising candidate.
-
Patent Agency Ranking
公开(公告)号：US10953114B2
公开(公告)日：2021-03-23
申请号：US16157961
申请日：2018-10-11
Applicant: Paul Scherrer Institut
Inventor： Martin Behe , Roger Schibli
IPC: A61K51/08 , A61K38/22 , G01N33/574 , C07K14/575 , C07K14/595 , C07B59/00 , C07K1/13 , C07K7/08
Abstract: A gastrin analogue shows high uptake in CCK-2 receptor positive tumors and simultaneously a very low accumulation in the kidneys. This is achieved by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is an amino acid replacing methionine and X is a chemical group attached to the peptide for diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. Very suitable compounds with respect to a high tumor to kidney ratio are mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine which can be oxidized easily which is a disadvantage for clinical application under GMP due to the forms which may occur. The elimination of the methionine leads to a lower affinity to oxidation which in general favors the tumor-kidney-ratio. Ideally, the methionine is replaced by norleucine. This PP-F11N mini gastrin exhibits currently the best tumor-kidney-ratio and is the most promising candidate.
-
公开(公告)号：US10434180B2
公开(公告)日：2019-10-08
申请号：US15214331
申请日：2016-07-19
Applicant: Innate Pharma , Paul Scherrer Institut
Inventor： Delphine Bregeon , Patrick Dennler , Christian Belmant , Laurent Gauthier , François Romagne , Eliane Fischer , Roger Schibli
IPC: A61K31/5517 , C07K16/00 , C07K16/30 , C07K19/00 , C07C217/08 , C07C223/02 , C07C229/26 , C07C233/62 , C07C247/04 , C07D225/08 , C07D257/08 , C07D277/06 , C07F9/50 , C12N9/10 , C12P21/00 , G01N33/68 , A61K47/48 , A61K47/68
Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.
-
公开(公告)号：US10132799B2
公开(公告)日：2018-11-20
申请号：US14414432
申请日：2013-07-10
Applicant: Innate Pharma , Paul Scherrer Institut
Inventor： Christian Belmant , Delphine Bregeon , Patrick Dennler , Eliane Fischer , François Romagne , Roger Schibli , Laurent Gauthier
IPC: A61K47/48 , C07K16/00 , C07K16/30 , C07K19/00 , A61K31/5517 , C07C217/08 , C07C223/02 , C07C229/26 , C07C233/62 , C07C247/04 , C07C323/12 , C07C323/60 , C07D225/08 , C07D257/08 , C07D277/06 , C07F9/50 , C12N9/10 , C12P21/00 , G01N33/68 , G01N33/532 , G01N33/50 , A61K47/68
Abstract: Provided is a method for the functionalization of immunoglobulins through the use of transglutaminase, including methods for screening functionalized antibodies for characteristics of interest, antibody compositions comprising a plurality of functionalized antibodies, and functionalized antibodies with rodent constant regions.
-
公开(公告)号：US09764038B2
公开(公告)日：2017-09-19
申请号：US14367840
申请日：2012-12-21
Applicant: Innate Pharma , Paul Scherrer Institut
Inventor： Patrick Dennler , Delphine Bregeon , Laurent Gauthier , François Romagné , Christian Belmant , Eliane Fischer , Roger Schibli
IPC: A61K47/48 , C07K16/18 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/00 , C07K19/00 , C07C217/08 , C07C223/02 , C07C229/26 , C07C233/62 , C07C247/04 , C07C323/12 , C07C323/60 , C07D225/08 , C07D257/08 , C07D277/06 , C07F9/50 , C12N9/10 , C12P21/00 , G01N33/68
CPC classification number: A61K47/6803 , A61K47/60 , A61K47/68 , A61K47/6807 , A61K47/6813 , A61K47/6817 , A61K47/6865 , A61K47/6871 , C07C217/08 , C07C223/02 , C07C229/26 , C07C233/62 , C07C247/04 , C07C323/12 , C07C323/60 , C07D225/08 , C07D257/08 , C07D277/06 , C07F9/5022 , C07K16/00 , C07K19/00 , C07K2317/40 , C12N9/1044 , C12P21/005 , G01N33/6854
Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.
-
公开(公告)号：US20130189287A1
公开(公告)日：2013-07-25
申请号：US13725382
申请日：2012-12-21
Applicant: Innate Pharma , Paul Scherrer Institut
Inventor： Delphine Bregeon , Patrick Dennler , Christian Belmant , Eliane Fischer , Laurent Gauthier , Francois Romagné , Roger Schibli
IPC: C07K19/00 , C12P21/00 , C12N9/10 , C07C323/60 , C07C323/12 , C07C247/04 , C07D225/08 , C07C217/08 , C07C229/26 , C07C233/62 , C07D277/06 , C07F9/50 , C07D257/08 , C07C223/02 , G01N33/68
CPC classification number: A61K47/6803 , A61K47/60 , A61K47/68 , A61K47/6807 , A61K47/6813 , A61K47/6817 , A61K47/6865 , A61K47/6871 , C07C217/08 , C07C223/02 , C07C229/26 , C07C233/62 , C07C247/04 , C07C323/12 , C07C323/60 , C07D225/08 , C07D257/08 , C07D277/06 , C07F9/5022 , C07K16/00 , C07K19/00 , C07K2317/40 , C12N9/1044 , C12P21/005 , G01N33/6854
Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions
Abstract translation: 本申请涉及用于免疫球蛋白功能化的方法，特别是与药物。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.029 seconds)
